The clinical management of H5N1 influenza virus infection in humans remains unclear. Combination chemotherapy with drugs that target different viral proteins might be more effective than monotherapy.
Methods
BALB/c mice were treated by oral gavage for 5 days with amantadine (1.5, 15 or 30 mg/kg/day) and oseltamivir (1 or 10 mg/kg/day) separately or in combination. Mice were challenged 24 h after initiation of treatment with 10 mouse 50% lethal doses of either amantadine-sensitive (having S31 in the M2 protein) or amantadine-resistant (having N31 in the M2 protein) recombinant A/Vietnam/1203/04 (H5N1) virus.
Results
Combination treatment with amantadine (15 or 30 mg/kg/day) and oseltamivir (10 mg/kg/day) provided greater protection (60% and 90%, respectively) against lethal infection with amantadine-sensitive H5N1 virus than did monotherapy. Moreover, spread of the virus to the brain was prevented by both combination regimens. The efficacy of the drug combinations against amantadine-resistant H5N1 virus was comparable to that of oseltamivir alone. Oseltamivir produced a dose-dependent effect against both recombinant H5N1 viruses (P<0.05) but did not provide complete protection against lethal infection. Importantly, no mutations in the HA, NA and M2 proteins were detected when the two drugs were used in combination.
Conclusions
Combination chemotherapy provided a survival advantage over single-agent treatment of mice inoculated with neurotropic H5N1 influenza virus. This strategy might be an option for the control of pandemic influenza viruses that are sensitive to amantadine. Combinations that include other drugs should be explored.
References
1.
StöhrK., EsveldM.Will vaccines be available for the next influenza pandemic?Science2004; 306: 2195–2196.
2.
BartlettJ.G., HaydenF.G.Influenza A (H5N1): will it be the next pandemic influenza? Are we ready?Ann Int Med2005; 143: 460–462.
3.
LiK.S., GuanY., WangJ.Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.Nature2004; 430: 209–213.
4.
WongS.S.Y., YuenK.Y.Avian influenza virus infections in humans.Chest2006; 129: 156–168.
5.
RiedelS.Crossing the species barrier: the threat of an avian influenza pandemic.Proc (Bayl Univ Med Cent)2006; 19: 16–20.
6.
World Health Organization. Avian influenza - spread of the virus to new countries.Weekly Epidemiol Rev2006; 81: 69–80.
7.
StephensonI., NicholsonK.G.Influenza: vaccination and treatment.Eur Respir J2001; 17: 1282–1293.
8.
HaydenF.G. (1996). Amantadine and rimantadine - clinical aspects. In Antiviral Drug Resistance; pp. 59–77. Edited by RichmanD.D.New York: John Wiley & Sons, Inc.
9.
MontoA.S.The role of antivirals in the control of influenza.Vaccine2003; 21: 1796–1800.
10.
Mckimm-BreschkinJ.L.Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance.Treat Respir Med2005; 4: 107–116.
11.
HayA.J., WolstenholmA.J., SkehelJ.J., SmithM.H.The molecular basis of the specific anti-influenza action of amantadine.EMBO J1985; 4: 3021–3024.
12.
HaydenF.G., KlimovA.I., TashiroM.Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.Antivir Ther2005; 10: 873–877.
13.
von ItzsteinM., WuW.Y., KokG.K.Rational design of potent sialidase-based inhibitors of influenza virus protection.Nature1993; 363: 418–423.
14.
BeigelJ.H., FarrarJ., HanA.M.Avian influenza A (H5N1) infection in humans.N Engl J Med2005; 353: 1374–1385.
15.
BrightR.A., MedinaM.J., XuX.Incidence of amantadine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause of concern.Lancet2005; 366: 1175–1181.
16.
BrightR.A., ShayD.K., ShuB., CoxN.J., KlimovA.I.Amantadine resistance among influenza A viruses isolated early during the 2005–2005 influenza season in the United States.JAMA2006; 295: 891–894.
17.
PeirisJ.S., YuW.C., LeungC.W.Re-emergence of fatal human influenza A subtype H5N1 disease.Lancet2004; 363: 617–619.
18.
IlyushinaN.A., GovorkovaE.A., WebsterR.G.Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia.Virology2005; 341: 102–106.
19.
HaydenF.G.Antiviral resistance in influenza viruses - implications for management and pandemic response.N Engl J Med2006; 354: 785–788.
20.
CheungC.L., RaynerL.M., SmithG.J.D.Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.J Infect Dis2006; 193: 1626–1629.
21.
GubarevaL.V., McCullersJ.A., BethellR.C., WebsterR.G.Characterization of influenza A/Hong Kong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice.J Infect Dis1998; 178: 1592–1596.
22.
LenevaI.A., RobertsN., GovorkovaE.A., GoloubevaO.G., WebsterR.G.The neuraminidase inhibitor GS 4101 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.Antiv Res2000; 48: 101–115.
23.
GovorkovaE.A., LenevaI.A., GoloubevaO.G., BushK., WebsterR.G.Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.Antimicrob Agents Chemother2001; 45: 2723–2732.
24.
YenH.L., MontoA.S., WebsterR.G., GovorkovaE.A.Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.J Infect Dis2005; 192: 665–672.
25.
GovorkovaE.A., FangH.B., TanM., WebsterR.G.Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.Antimicrob Agents Chemother2004; 48: 4855–4863.
26.
IlyushinaN.A., BovinN.V., WebsterR.G., GovorkovaE.A.Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.Antiviral Res2006; 70: 121–131.
27.
WilsonS.Z., KnightV., WydeP.R., DrakeS., CouchR.B.Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice.Antimicrob Agents Chemother1980; 17: 642–648.
28.
HaydenF.G.Combinations of antiviral agents for treatment of influenza virus infections.J Antimicrob Chemother1986; 18Suppl B: 77–83.
29.
ZhirnovO.P.High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combinations.J Med Virol1987; 21: 161–167.
30.
SmeeD.F., BaileyK.W., MorrisonA.C., SidwellR.W.Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin.Chemotherapy2002; 48: 88–93.
31.
GovorkovaE.A., RehgJ.E., KraussS.Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004.J Virol2005; 79: 2191–2198.
32.
ParkC.H., IshinakaM., TakadaA.The invasion routes of neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after respiratory infection in mice.Arch Virol2002; 147: 1425–1436.
33.
SpecterR.Transport of amantadine and rimantadine through the blood-brain barrier.J Pharmacol Exp Ther1988; 244: 516–519.
34.
DeleuD., NorthwayM.G., HanssensY.Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.Clin Pharmacokinet2002; 41: 261–309.
35.
HoffmannE., KraussS., PerezD., WebbyR., WebsterR.G.Eight-plasmid system for rapid generation of influenza virus vaccines.Vaccine2002; 20: 3165–3170.
36.
HoffmannE., NeumannG., KawaokaY., HobomG., WebsterR.G.A DNA transfection system for generation of influenza A virus from eight plasmids.Proc Natl Acad Sci U S A2000; 97: 6108–6113.
37.
HoffmannE., LipatovA.S., WebbyR.J., GovorkovaE.A., WebsterR.G.Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines.Proc Natl Acad Sci U S A2005; 102: 12915–12920.
38.
HaydenF.G., GoteK.M., DouglasR.G.Plaque inhibition assay for drug susceptibility testing of influenza viruses.Antimicrob Agents Chemother1980; 17: 865–870.
CoxD.R.Regression models and life-tables.J R Stat Soc B1972; 34: 187–220.
41.
WardP., SmallI., SmithJ., SuterP., DutkowskiR.Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.J Antimicrob Chemother2005; 55Suppl 1: i5–i21.
42.
NicholsonK.G., WiselkaM.J.Amantadine for influenza A.British Med J1991; 302: 425–426.
43.
SweenyD.J., LynchG., BidgoodA.M., LewW., WangK.Y., CundyK.C.Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.Drug Metab Dispos2000; 28: 737–741.
44.
ScholtissekC., QuackG., KlenkH.D., WebsterR.G.How to overcome resistance of influenza A viruses against adamantane derivatives?Antiviral Res1998; 37: 83–95.
